Generation of a Predictive Melphalan Resistance Index by Drug Screen of B-Cell Cancer Cell Lines

Martin Boegsted(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Johanne Marie Holst(Aalborg University Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Hans Erik Johnsen(Herlev Hospital), Steffen Falgreen(Chr. Hansen (Denmark)), Suzette Sørensen(North Denmark Region), Anne Bukh(Aalborg University Hospital), Kirsten Fogd(Aalborg University Hospital), Mette Nyegaard(Statens Serum Institut)

PLoS ONE

April 29, 2011

10.1371/journal.pone.0019322

Cited by 31

Related Papers

Common variants conferring risk of schizophrenia

|Nature|2009|1.7k

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362